- Fast Track designation highlights the potential for momelotinib to address the significant unmet needs of patients with Intermediate/High-Risk myelofibrosis who have previously received a JAK...
- MOMENTUM Phase 3 clinical trial planned for launch in Q4 2019; topline efficacy data anticipated in Q4 2021 – - World renowned myelofibrosis expert Dr. Srdan Verstovsek named Chief...
- Sierra management and distinguished oncologists Professor Johann de Bono and Dr. Rebecca Kristeleit discuss clinical findings and possible next steps for SRA737 - - Sierra reported SRA737...
